ArticleArchives of microbiology2026
Antibiofilm efficacy and genomic characterization of a lytic bacteriophage targeting MDR uropathogenic Escherichia coli.
Article in Archives of microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Uropathogenic Multidrug-resistant Escherichia coli is a leading cause of persistent urinary tract infections, largely because of its ability to form antibiotic-tolerant biofilms. Isolation of bacteriophage UHEC was carried out from hospital sewerage utilizing a third-generation cephalosporin-resistant E. coli clinical isolate EC-11. The phage was characterized by plaque morphology, host range, growth kinetics, environmental stability, planktonic growth inhibition, and biofilm removal capacity. Genome sequencing and bioinformatic analyses were done to assess genomic traits, safety, and phylogeny placement. UHEC formed small, clear plaques and exhibited a narrow host range limited to selected E. coli clinical isolates. In planktonic cultures, UHEC produced rapid and dose-dependent growth suppression. UHEC demonstrated pronounced anti-biofilm activity against EC-11 biofilms at different stages of maturation. Treatment of 24- and 48-h-old biofilms resulted in 3.3-3.8 log reductions after 24 h of exposure, corresponding to > 99.9% reduction compared with untreated controls. Although reduced efficacy was observed against more mature biofilms (72-96 h), extended phage exposure still produced statistically significant reductions of up to 0.9 log. UHEC remained stable across pH ranges of 6-9, moderate temperatures, and long term storage at 4 °C and -80 °C. UHEC has a latency period of 25 min with average burst size of 112 PFU/cell. Genomic analysis identified a 58.8 kbp double-stranded DNA genome lacking lysogeny, virulency, or antimicrobial resistance gene. Phylogenetic analyses placed UHEC among T7-like lytic bacteriophages within the class Caudoviricetes. Conclusively, UHEC is a genetically safe, lytic bacteriophage with notable anti-biofilm activity against MDR uropathogenic E. coli, supporting its potential utility in future preclinical investigations.
Indexed as
Identifiers
42377507What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.